Hemorrhage

Allergic -  allergic reactions ranging from mild to short-term urticarial rashes to severe anaphylactoid
reactions. discontinue immediately if such signs appear.

Cardiovascular-   thromboembolic reactions may occur particularly after high doses or in patients
with thrombotic risk factors.

Special Precautions-
Potential disease transmission-   AICC is made from human plasma . Products made from plasma
may contain infectious agents such as viruses, that can cause disease. The risk can be reduced by
effetive screening of the donor , testing for infectious agents

Idenification of clotting deficiency- use AICC only in patients with circulating inhibitors to one or more
coagulation factors and do not use it for the treatment of bleeding episodes resulting from coagulation
factor deficiency. Do not give it to patients with significant signs of disseminated intravascular
coagulation DIC or fibronolysis

High doses - give high doses of AICC only as long as absolutely necessary to stop bleeding

Concomittant antifibrinolytics- it has  been reported that AICC and antifibronolytics have been given
simultaneously without complications. It is however, recommended not to use antifibrinolysis until
12 hours after the administration of AICC.

Anamnestic response- anamnestic responses with rises in factor VIII  inhibitor titer have been
observed in 20% of the cases.

Viral infections- individuals who receive infusions of blood or plasma products may develop
signs and/or symptoms of some viral infections, paricularly non-A , non-B hepatitis

Pregnancy- not known whether AICC can cause fetal harm when administered to a pregnant woman.
Give to a pregnant woman only if required

Children-  no data  are available regarding use of AICC in children

Monitoring- monitor patients receiving AICC 100units/kg of body weight for the development of
DIC and/or symptoms of acute coronary ischemia.

Indication-
Hemorrhage

Dosage-
Recommended dosage- as  general gideline a dosage range of 50 to 100 units of AICC per kg of body
weight is recommended.

1. Some viruses such as paraviris B19 or hepatitis A are particularly difficult to remove or
    inactivate at this time.

2. Paravirus B19 most seriously affect pregnant woman or immune-compromised individuals

3. Symptoms of paravirus B19 include fever, drowsiness, chills, and runny nose followed by
    2 weeks later by a rash and joint pain.

4. Evidence of hepatitis A several days or weeks of poor appetite, tiredness, and low grade
    fever, followed by nausea, vomiting, and pain in the belly. Dark urine and yellow complexion
    are also common  symptoms.

5. Encourage patients to consult their health care provider if such symptoms develop.

Pregnancy-
Not known whether AICC can cause fetal harm when administered to a pregnant woman.
Give to a pregnant woman only if required

Children- 
No data  are available regarding use of AICC in children